Drug Profile
Research programme: microRNA therapeutics - GlaxoSmithKline/Regulus Therapeutics
Alternative Names: miR-122 inhibitors - GlaxoSmithKline/Regulus; miR-146 inhibitors - GlaxoSmithKline/Regulus; miR-155 inhibitors - GlaxoSmithKline/Regulus; miR-181a inhibitors - GlaxoSmithKline/RegulusLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Regulus Therapeutics LLC
- Developer GSK; Regulus Therapeutics
- Class MicroRNAs
- Mechanism of Action MicroRNA inhibitors; MIRN122 microRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis C; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 09 May 2014 Preclinical development is ongoing for Inflammation in USA (Regulus 10-Q)